Research Applications

CJC-1295 no DAC is primarily studied for its potential therapeutic applications in enhancing growth hormone (GH) secretion. This peptide is often investigated in clinical and preclinical research related to metabolic health, body composition, and age-related decline in GH levels. Specific therapeutic areas of interest include obesity management, lipodystrophy, and muscle wasting disorders. Although CJC-1295 no DAC does not currently have FDA-approved uses, it is closely related to other peptides like Tesamorelin, which is approved for the treatment of HIV-associated lipodystrophy.

History & Development

CJC-1295 no DAC was developed by the pharmaceutical company ConjuChem Biotechnologies in the early 2000s. The peptide was designed to overcome the limitations of traditional growth hormone-releasing hormones by incorporating structural modifications that enhance its stability and efficacy. While it has not received FDA approval, its design features include a modified amino acid sequence that provides resistance to enzymatic degradation, allowing for longer half-life and sustained GH release.

Mechanism of Action

CJC-1295 no DAC functions by binding to the growth hormone secretagogue receptor (GHSR) in the hypothalamus, stimulating the endogenous release of growth hormone from the anterior pituitary gland. This action leads to an increase in circulating GH levels, which subsequently enhances insulin-like growth factor 1 (IGF-1) production in the liver. The downstream effects of GH and IGF-1 include improved protein synthesis, fat metabolism, and overall anabolic activity in muscle and other tissues.

Clinical Data

Published studies suggest that CJC-1295 no DAC may significantly impact body composition and metabolic parameters. For instance, a Phase 2 clinical trial led by 'Rosenfeld et al.' demonstrated that participants receiving CJC-1295 no DAC experienced a notable reduction in body fat and an increase in lean muscle mass. Additionally, other studies have indicated improvements in insulin sensitivity and lipid profiles, although specific numerical data vary among trials.

How It Compares

When compared to related peptides, CJC-1295 no DAC exhibits distinct differences in mechanism of action and pharmacokinetics. For example, Ipamorelin is another GH secretagogue that primarily stimulates GH release without significantly affecting cortisol levels, making it a popular alternative for certain applications. In contrast, CJC-1295 no DAC offers a longer half-life due to its structural modifications, allowing for less frequent dosing. Additionally, while Sermorelin is a shorter peptide that also stimulates GH release, it lacks the extended duration of action provided by CJC-1295 no DAC.

Solubility & Storage

The recommended reconstitution solvent for CJC-1295 no DAC is sterile water or bacteriostatic water, which helps maintain the integrity of the peptide. Once reconstituted, the peptide should be stored at a temperature of 2-8°C (36-46°F) to ensure stability. The lyophilized form is stable at room temperature, but prolonged exposure should be avoided. Typically, reconstituted CJC-1295 no DAC remains stable for up to 30 days when stored correctly.

Future Research Directions

Future research directions for CJC-1295 no DAC are focused on exploring its potential in treating age-related conditions and metabolic disorders. Researchers are investigating its efficacy in promoting muscle growth in sarcopenia and its effects on overall longevity. Additionally, there is emerging off-label interest in the use of CJC-1295 no DAC for performance enhancement among athletes and in the context of anti-aging therapies. Ongoing studies aim to further elucidate its safety profile and long-term effects on metabolic health.